Copyright
©2010 Baishideng.
World J Hepatol. May 27, 2010; 2(5): 180-184
Published online May 27, 2010. doi: 10.4254/wjh.v2.i5.180
Published online May 27, 2010. doi: 10.4254/wjh.v2.i5.180
Total No. of patients | 52 |
Sex | 30 F: 22 M |
Mean age (range) | 29.5 (15-54) years |
Mean HbS (range) | 74.4% (66%-89%) |
Mean HbF (range) | 22.5% (9.6%-33.6%) |
G6PD deficiency | 12 (23.1%) |
Mean HCV-RNA viral load (range) | 986330 IU/mL (range 12762-3329282 IU/mL) |
HCV genotype | |
genotype 1 | 13 (8 non-responders) |
genotype 2 | 20 (2 non-responders) |
genotype 3 | 6 |
genotype 4 | 8 (4 non-responders) |
genotype 5 | 1 (1 non-responder) |
not available | 4 |
Mean Hb level | |
At start of treatment | 10.2 g/dL (7.5-11.5 g/dL) |
At 3 mo of treatment | 10.4 g/dL (8.9-11.2 g/dL) |
At 6 mo of treatment | 10.35 g/dL (8.5-11.9 g/dL) |
At the end of treatment | 10.3 g/dL (8.2-11.7 g/dL) |
SVR at 6 mo after the end of treatment | 37 (71.2%) |
- Citation: Issa H. Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia. World J Hepatol 2010; 2(5): 180-184
- URL: https://www.wjgnet.com/1948-5182/full/v2/i5/180.htm
- DOI: https://dx.doi.org/10.4254/wjh.v2.i5.180